CureTech Ltd. is a biotechnology company developing novel, broad-spectrum, immune modulating products for the treatment and control of cancer.
Building on the broad experience of its management, we have established a well-balanced portfolio of cancer therapies with our lead humanized antibody product, pidilizumab (CT-011), in Phase II clinical testing. Our products are antibodies and peptide-based vaccines designed to modulate the immune response allowing it to exert its anti-cancer activity in an effective manner. An extensive portfolio of issued patents and pending patent applications worldwide protects all our products and their anticipated medical uses.
The distinctive characteristic of our products is that their efficacy peaks in the presence of an actively growing cancer, rendering them most suitable for the treatment of human malignant diseases. Our lead monoclonal antibody product, pidilizumab (CT-011), was shown to effectively attenuate tumor growth and eliminate tumor metastases in a variety of model systems. A Phase II program has been initiated including 3 sponsored studies: the first, a Phase II clinical trial in patients with diffuse large B cell lymphoma has been completed. Enrolement of patients to 2 additional studies in patients with metastatic colorectal cancer and metastatic melanoma has been completed. In addition to these 2 studies, several investigator-initiated studies are ongoing.
CureTech is a privately held company with offices and laboratories located in Yavne, Israel.